Why the study?
People living with HIV have twice the risk of atherosclerotic vascular disease, where inflammation plays a critical role, but limitations exist with current F-18 FDG PET/CT imaging.
Does radionuclide imaging (such as F-18 FDG PET/CT) accurately assess arterial inflammation and cardiovascular risk in people living with HIV?
Population
People living with HIV infection
Design
Review
Authors
Loading...
Viable for arterial inflammation assessment in HIV; leaves open clinical adoption pending prospective outcome trials.
Does radionuclide imaging (such as F-18 FDG PET/CT) accurately assess arterial inflammation and cardiovascular risk in people living with HIV?
Radionuclide imaging, particularly F-18 FDG PET/CT, is a valuable tool for quantifying arterial inflammation and assessing cardiovascular risk in HIV-infected patients, though newer targeted probes are being explored to improve specificity.
Lawal et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: